Last reviewed · How we verify
Recombinant Human Insulin Patch ZJSRM2021
Recombinant human insulin delivered via transdermal patch replaces deficient endogenous insulin to regulate blood glucose levels.
Recombinant human insulin delivered via transdermal patch replaces deficient endogenous insulin to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Recombinant Human Insulin Patch ZJSRM2021 |
|---|---|
| Sponsor | Zhejiang Provincial People's Hospital |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a recombinant human insulin formulation administered through a transdermal patch system, allowing insulin to be absorbed through the skin rather than via injection. Insulin binds to insulin receptors on target cells, promoting glucose uptake and utilization while suppressing hepatic glucose production, thereby normalizing blood glucose in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions (or patch site reactions)
- Weight gain
- Lipodystrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: